Indaptus Therapeutics (INDP) Projected to Announce Quarterly Earnings on Monday

Indaptus Therapeutics (NASDAQ:INDP) is expected to be announcing its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect the company to announce earnings of ($1.57) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.87) by $1.64.

Indaptus Therapeutics Price Performance

INDP opened at $1.18 on Monday. The business’s fifty day simple moving average is $2.70 and its 200 day simple moving average is $2.27. Indaptus Therapeutics has a 52 week low of $0.92 and a 52 week high of $8.69. The stock has a market cap of $133.62 million, a PE ratio of -0.08 and a beta of 1.18.

Hedge Funds Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on INDP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Indaptus Therapeutics currently has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.